FDA Policy for REMS Reqmts during COVID-19

Health Care, Pharma Industry, Strategic Planning

FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.

Read the Policy now

 

 

Related Education Resources.

All Resources

Current Challenges in Cell and Gene Therapy

Topic: Regulatory

Webinar

Free

Challenges of the Cell, Gene, CAR-T and Personalized Medicine Supply Chains

Topics: Cold Chain, Conference, Supply Chain

Video

Members

Video on eTMF Requirements provided by Steve Jacobs, Chairman at Global BioPharm Solutions.

Topics: Pharma Industry, Strategic Planning

Video

Members

Become a member

Global Clinical Supplies Group

Join GCSG for full access...

to our educational resources, conference materials and our directory of more than 480 Clinical Supply colleagues. Experience the culture of collaboration, It only takes approximately 3 minutes 22 seconds.

Please note that membership is included and FREE of charge when you sign up for an event.

Join Renew